Literature DB >> 30529925

Multiple sclerosis risk factors contribute to onset heterogeneity.

Farren B S Briggs1, Justin C Yu2, Mary F Davis3, Jinghong Jiangyang4, Shannon Fu5, Erica Parrotta6, Douglas D Gunzler7, Daniel Ontaneda8.   

Abstract

BACKGROUND: The phenotypic presentation of multiple sclerosis (MS) may predict long-term outcomes and little is known about factors contributing to heterogeneity at MS onset. Given temporality, it is likely MS risk factors also influence presentation of the disease near onset.
METHODS: Using a retrospective cross-sectional study of MS cases, we investigated: age of onset (AOO), number of impaired functional domains (NIFDs), time to second relapse (TT2R), and early relapse activity (ERA). Machine learning variable selection was applied to epidemiologic data for each outcome, followed by multivariable regression models. The models were further adjusted for HLA-DRB1*15:01 carrier status and a MS genetic risk score (GRS). The TT2R and ERA analyses were restricted to relapsing remitting MS cases.
RESULTS: HLA-DRB1*15:01, GRS, and smoking were associated with earlier AOO. Cases who were male, obese, had lower education, or had primary progressive MS were older at onset. For NIFDs, those with relapsing remitting MS and of lower SES had increased NIFDs. Among relapsing remitting cases, those who were older at onset, obese, and had polyfocal presentation had shorter TT2R, while ERA was greater among those younger at onset and who were obese.
CONCLUSION: Individual characteristics including age, genetic profiles, obesity, and smoking status contribute to heterogeneity in disease presentation and modulate early disease course evolution.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology; Genetics; Multiple sclerosis; Onset; Risk factors

Mesh:

Substances:

Year:  2018        PMID: 30529925     DOI: 10.1016/j.msard.2018.12.007

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  15 in total

1.  New age for progressive multiple sclerosis.

Authors:  Jaime Imitola
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-19       Impact factor: 11.205

Review 2.  A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases.

Authors:  I S Stafford; M Kellermann; E Mossotto; R M Beattie; B D MacArthur; S Ennis
Journal:  NPJ Digit Med       Date:  2020-03-09

Review 3.  Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.

Authors:  Insha Zahoor; Shailendra Giri
Journal:  Clin Rev Allergy Immunol       Date:  2021-04       Impact factor: 8.667

4.  Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.

Authors:  Elina Misicka; Corriene Sept; Farren B S Briggs
Journal:  J Neurol       Date:  2020-04-24       Impact factor: 4.849

Review 5.  Genetics and functional genomics of multiple sclerosis.

Authors:  Woori Kim; Nikolaos A Patsopoulos
Journal:  Semin Immunopathol       Date:  2022-01-12       Impact factor: 9.623

Review 6.  Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.

Authors:  Marijne Vandebergh; Nicolas Degryse; Bénédicte Dubois; An Goris
Journal:  J Neurol       Date:  2022-04-02       Impact factor: 6.682

7.  Associations between smoking and walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis.

Authors:  Turhan Kahraman; Asiye Tuba Ozdogar; Zuhal Abasiyanik; Serkan Ozakbas
Journal:  Acta Neurol Belg       Date:  2020-03-28       Impact factor: 2.396

Review 8.  Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS).

Authors:  Amnon A Berger; Emily R Sottosanti; Ariel Winnick; Jonathan Izygon; Kevin Berardino; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Neurol Int       Date:  2021-05-19

9.  The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis.

Authors:  Naeim Ehtesham; Maryam Zare Rafie; Meysam Mosallaei
Journal:  BMC Neurol       Date:  2021-06-28       Impact factor: 2.474

10.  Onset Symptom Clusters in Multiple Sclerosis: Characteristics, Comorbidities, and Risk Factors.

Authors:  Vladeta Ajdacic-Gross; Nina Steinemann; Gábor Horváth; Stephanie Rodgers; Marco Kaufmann; Yanhua Xu; Christian P Kamm; Jürg Kesselring; Zina-Mary Manjaly; Chiara Zecca; Pasquale Calabrese; Milo A Puhan; Viktor von Wyl
Journal:  Front Neurol       Date:  2021-07-06       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.